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ABSTRACT
Cis-diamminedichloroplatinum(II) (cisplatin, cDDP) is an effective 
chemotherapeutic agent that induces DNA double strand breaks (DSBs), primarily 
in replicating cells. Generally, such DSBs can be repaired by the classical or backup 
non-homologous end joining (c-NHEJ/b-NHEJ) or homologous recombination (HR). 
Therefore, inhibiting these pathways in cancer cells should enhance the efficiency of 
cDDP treatments. Indeed, inhibition of HR by hyperthermia (HT) sensitizes cancer 
cells to cDDP and in the Netherlands this combination is a standard treatment option 
for recurrent cervical cancer after previous radiotherapy. Additionally, cDDP has been 
demonstrated to disrupt c-NHEJ, which likely further increases the treatment efficacy. 
However, if one of these pathways is blocked, DSB repair functions can be sustained 
by the Poly-(ADP-ribose)-polymerase1 (PARP1)-dependent b-NHEJ. Therefore, 
disabling b-NHEJ should, in principle, further inhibit the repair of cDDP-induced DNA 
lesions and enhance the toxicity of thermochemotherapy. To explore this hypothesis, 
we treated a panel of cancer cell lines with HT, cDDP and a PARP1-i and measured 
various end-point relevant in cancer treatment. Our results demonstrate that PARP1-i 
does not considerably increase the efficacy of HT combined with standard, commonly 
used cDDP concentrations. However, in the presence of a PARP1-i, ten-fold lower 
concentration of cDDP can be used to induce similar cytotoxic effects. PARP1 inhibition 
may thus permit a substantial lowering of cDDP concentrations without diminishing 
treatment efficacy, potentially reducing systemic side effects.
INTRODUCTION
Cisplatin (cis-diamminedichloroplatinum(II), cDDP), 
is one of the most potent and widely used chemotherapeutic 
agents. cDDP has been successfully applied in treating 
many different tumor types, including head and neck, 
lung, testis, ovarian, cervix and breast [1, 2]. cDDP induces 
formation of intra- and interstrand crosslinks, which may 
induce DNA single and double strand breaks (SSBs and 
DSBs) in replicating cells [3, 4]. The accumulation of 
unrepaired DNA lesions, particularly DSBs, can lead 
to cell death. In mammalian cells, DSBs are repaired by 
mainly two major pathways: the classical non-homologous 
end joining (c-NHEJ) and the homologous recombination 
(HR). HR is mainly active in S- and G2-phase, ensures 
accurate repair by using the undamaged sister chromatid 
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as a template and involves, among others, BRCA2 and 
RAD51 [5]. Mild hyperthermia (HT), 1 h at 41–42.5°C, can 
disrupt this pathway temporarily by inducing degradation 
of BRCA2 and preventing the recruitment of RAD51 to 
DSBs [6]. c-NHEJ is active in all cell cycle phases, rejoins 
the break ends without the requirement for homologous 
template and is therefore considered to be more error prone 
[7–9]. Besides inducing DNA breaks, cDDP has also been 
shown to disrupt c-NHEJ [10–13].
The combination of cDDP and HT has been shown 
to be an effective clinical modality and is the standard 
treatment for previously irradiated patients with recurrent 
cervical cancer in the Netherlands [14]. Nevertheless, 
commonly used dose of cDDP can be very toxic for 
a substantial percentage of patients due to sometimes 
irreversible neural toxicity (hearing loss, numbness and 
tingling of the extremities) and kidney failure [15, 16]. 
Kidney failure is particularly dreaded in women with 
advanced cervical cancer in whom kidney function is 
already impaired by renal obstruction due to the tumor. 
Therefore, a large number of patients would benefit 
it the required dose of cDDP could be reduced without 
compromising tumor control. 
Tumor resistance to cDDP plus HT may not only 
be explained by an insufficient cDDP dose, but also 
by the existence of a third DNA-repair pathway, so-
called back-up NHEJ (b-NHEJ), which becomes active 
when either or both c-NHEJ and HR are impaired [17]. 
Poly-(ADP-ribose)-polymerase1 (PARP1) is essential 
for functioning of b-NHEJ [18, 19], and at least partly 
explains the accumulation of DSBs. Additional benefits 
of this approach may come from the observations that 
PARP1 plays a crucial role in regulating replication fork 
progression. Collapsed replication forks caused by a 
PARP1-i are converted to DSBs and require HR for repair 
[20]. In HR deficient cells, including cells harboring 
inactivation mutations in BRCA1 or BRCA2 and cells 
suffering from a HT-induced BRCA2 degradation, such 
lesions become highly cytotoxic in what can be considered 
a form of synthetic lethality [6, 20–24]. Importantly, 
PARP1 inhibitors have already been in multiple clinical 
trials in BRCA negative breast and ovarian cancers, and 
generally show favorable clinical profile [25, 26]. 
Here we set out to test, in vitro, whether the efficacy 
of cDDP+HT modality can benefit from the inhibition 
of PARP1. We focused on two interrelated aspects of 
such therapeutic strategy. First, we investigated whether 
PARP1-i can enhance the cytotoxicity of the standard 
cDDP+HT regimen. Second, we asked whether addition 
of PARP1-i can allow significant reduction of the overall 
cDDP dose, while maintaining the cytotoxic potential 
of the treatment. This is a clinically relevant question, 
particularly in the case that inhibition of PARP1 does not 
significantly alter the efficacy of HT when combined with 
standard cDDP doses, due to relatively high cytotoxicity of 
the two modality approach. Given that the concentrations 
of cDDP in necrotic or poorly vascularized tumor areas 
are likely low, reducing the cDDP dose required for 
efficient cell killing by co-administering PARP1-i may 
allow maintaining local tumor control while limiting 
the systemic side effects associated with standard cDDP 
concentrations.
RESULTS 
Mild hyperthermia induces cell cycle 
arrest, apoptosis and inhibits homologous 
recombination 
To determine the effect of HT on R1, SiHa and 
HeLa cells, we first measured changes in cell cycle 
distribution and induction of apoptosis. In the cell cycle 
analysis (Figure 1A) a G2-arrest was observed 16 h after 
treating cells for 1 h with 42°C. This effect was moderate 
for R1 cells and more pronounced for SiHa and HeLa 
cells. Flow cytometric analysis of DNA content showed 
a 20% increase in apoptosis for all cell lines (Figure 1B). 
Next, We measured the effects of HT on HR activity by 
quantifying accumulation of HR factor RAD51 on alpha-
particle induced DSBs. Consistently with previously 
published results, HT treatment temporarily abrogated 
accumulation of RAD51 on DSB sites in all cell lines 
(Figure 1C), confirming inactivation of HR.
PARP1-i sensitizes cells moderately to 
combinational treatment of cDDP with 
hyperthermia
Having confirmed that HR is inhibited by HT in 
the used cell lines, we set out to determine the effects 
of PARP1 inhibition on the cytotoxicity of cDDP+HT 
treatment. To this end, clonogenic survival assays were 
conducted as schematically shown. Clonogenic assays 
were conducted to investigate the effect of the different 
treatments on cell survival Figure 2A. In Figure 2B, 
percentages of survival are normalized to the untreated 
samples. We observed a ~50% decrease in cell survival 
after 1 h cDDP (5 µM) treatment alone. Hyperthermia 
as a monotherapy was less effective than treatment with 
a PARP1-i. Combining the PARP1-i with cDDP caused 
a slight decrease in cell survival, compared to samples 
treated with cDDP only. The combination of cDDP and 
HT was highly cytotoxic and killed > 85% of cells, while 
the combination of hyperthermia and PARP1-i was less 
effective. The triple treatment with cDDP, PARP1-i and 
HT resulted in a slightly lower cell survival than the 
double treatment of cDDP and hyperthermia, but this 
difference was not statistically significant.
To further explore the effects of various 
treatments, the induction of DSBs was quantified by 
counting γ-H2AX foci (Figure 2C). In R1 cells, cDDP 
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treatment induced around 20 γ-H2AX foci, while in 
SiHa and HeLa a 3–4 fold more γ-H2AX foci were 
found 24 h after treatment with cDDP. Treatment 
with hyperthermia and cDDP induced a similar 
amount of DSBs (70–90) as the triple modality. The 
number of detected DSBs was relatively low after the 
single treatment with PARP1-i or hyperthermia. The 
combination of the PARP1-i with hyperthermia resulted 
in a slight increase in the number of DSBs in HeLa 
cells, but not in SiHa and R1 cells.
DNA content analysis was performed 48 h after the 
various treatments to test whether apoptosis is responsible 
for the observed induction of cell death (Figure 2D). All 
three cell lines showed > 20% of apoptotic cells after 
the single and double modalities, while after the triple 
treatment the induction of apoptosis increased significantly 
(up to 25–30%).
Cell cycle distribution was not significantly affected 
16 h after treatments, except for the combination of 
hyperthermia and cDDP and the triple combination, which 
caused a ~30–55% increase in accumulation of cells in 
S-phase (Figure 2E). These results indicate that addition of 
PARP1-i moderately sensitizes cells to the combinational 
cDDP+HT treatment, mainly by increasing apoptosis. 
Cell death and cell cycle arrest are prominent 
in cells treated with PARP1-i, cDDP and 
hyperthermia
To study the cell cycle distribution in more detail, 
we followed cells using time-lapse microscopy for 96 h, 
starting immediately after the various treatments. In 
Figure 3A representative images of the cells are shown 
at 0 h (left column) and 96 h (right column) after the 
end of the indicated treatments. SiHa and HeLa cells 
ceased to grow rapidly after any treatment containing 
cDDP. However, thermochemotherapy alone (cDDP+HT) 
as well as the triple treatment were the most toxic for 
these cells (last two rows of pictures). The combination 
treatments had similar effects on the R1 cells, although 
they appeared to be less sensitive to cDDP alone. After 
96 h, in cDDP+HT or cDDP+HT+PARP1-i treatments, 
most of the R1 cells died, while the SiHa and HeLa cells 
interrupted their cell cycle progression (Figure 3C). Cells 
that did not divide for over 50 h, but did not die, were 
regarded to be in ‘cell cycle arrest’. Nevertheless, the cell 
cycle time was unaffected in the surviving cells under the 
different treatment conditions, both in the first and second 
generation post-treatment, except for cells treated with 
Figure 1: Sensitivity of cells to hyperthermia. (A) Cell cycle analysis were determined via FACS analysis after BrdU incorporation. 
A G2-arrest is observed after HT treatment. (B) Apoptosis levels were studied using the Nicoletti assay. HT induced apoptosis in all cell 
lines. (C). Representative pictures of co-localization of γ-H2AX and RAD51 foci on α-irradiation tracks in untreated cells and after HT 
treatment. RAD51 is no longer detected 30 min after HT, indicating that HR is not active. The bar graph with the standard error of the mean 
shows the mean of at least three independent experiments. For each condition more than 300 cells were analyzed.
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cDDP+HT and the triple combination, where the few 
surviving cells were all in cell cycle arrest (Figure 3B).
Adding PARP1-i to cDDP+HT treatment allows 
lowering cDDP dose while maintaining similar 
levels of cytotoxicity 
The effects PARP1-i could be masked by the 
relatively high cytotoxicity of the cDDP+HT combination 
treatment. To test this hypothesis, we compared the 
effectiveness of the commonly used dose of cDDP 
concentration (5 μM for 1 h; cDDP/C) to a tenfold lower 
cDDP concentration (0.5 μM for 1 h; cDDP/L). We found 
similar levels of cell death (Figure 4A) in cells treated 
with either cDDP/L+HT+PARP1-i or cDDP/C+HT (R1: 
p = 0.10; SiHa: p = 0.86; HeLa: p = 0.22). Time-lapse 
microscope analysis confirmed these results at 96 h after 
treatment (Figure 4B). Moreover, clonogenic survival 
analysis showed that cDDP/L+HT+PARP1-i had similar 
cytotoxic effects as the combination of cDDP/C+HT 
Figure 2: Effects of PARP1-i (100 μM NU1025/continuously), HT (42°C/1 h), cDDP (5 μM/1 h). (A) Overview of treatment 
schemes for different experiments represented in B–E. (B) Clonogenic assays were conducted in order to study the cell survival after 10–12 
days post-treatment. No significant differences were found between HT+cDDP and cDDP + HT + PARP1-i. (R1: p = 0.10, SiHa: p = 0.12, 
HeLa: p = 0.10). (C) DNA DSBs were analyzed using the γ-H2AX assay. The induction of DSBs in SiHa and HeLa after cDDP treatment is 
3-4 times higher than in R1 cells. Nonetheless, all three cells lines show around 70–80 DSBs after cDDP+HT or cDDP+HT+PARP1-i. (D) 
The Nicoletti assay was performed to observe apoptosis levels after different treatments. The triple combination treatment gave the highest 
levels of apoptosis. (E) Cell cycle was determined via FACS analysis after BrdU incorporation. cDDP+HT and cDDP+HT+PARP1-i show 
a slight increase in cells in S-phase. Graph bars represent mean of at least three experiments with standard error of the mean. Asterisks 
indicate the significant differences compared to the untreated sample (ctrl), this was tested using the non-parametric Mann-Whitney test. 
*p < 0.05, **p < 0.01, ***p < 0.001.
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(Figure 4C). No significant differences were found in 
R1, SiHa and HeLa cells (p = 0.10, p = 0.70 and p = 0.20 
respectively). These results demonstrate that using a 
PARP1-i could allow lowering cDDP dosage without 
significantly affecting the treatment efficacy. This might 
be of great importance for patients who do not tolerate the 
standard concentration of cDDP, due to toxicity.  
DISCUSSION
Our results show that the combination of a standard 
cDDP-dose plus HT already yields a high tumor kill. 
This agrees with clinical studies in women with recurrent 
cervical cancer [27]. Although, the addition of PARP1-i in 
an experimental setting only gives a minor enhancement 
of this effect, a moderate increase in cell death was 
observed in all cases. Moreover, at a ten-fold-lower cDDP 
concentration plus HT, the loss of tumorcidal effect can 
be compensated by PARP1 inhibition. These findings 
are consistent both in terms of cell surviving fraction, 
γ-H2AX foci staining and apoptosis. The advantage of the 
low-dose cDDP+HT+PARP1-i treatment, may be a lower 
cDDP related toxicity in patients. Our speculation would 
be that inhibition of PARP1-i does not cause an induction 
of DNA double strand breaks, but interferes with the 
b-NHEJ to prevent repair of double strand breaks [18, 19].
In the Netherlands, combinational treatment 
of cDDP and hyperthermia is one of the standard 
Figure 3: Time-lapse microscopy analysis 0 and 96 h after combination treatments with PARP1-i (100 μM NU1025/
continuously), HT (42°C/1 h), cDDP (5 μM/1 h). (A) Representative pictures of cells directly after treatment (0 h) and four days 
after treatment (96 h). (B) Cell division times of two generations post treatment. Cells that did not divide for over 50 h, but did not die, 
were regarded to be in ‘cell cycle arrest’. R1 cells have a shorter cell division time than SiHa and HeLa cells. But no significant differences 
were found after any of the treatments compared to the untreated cells. Graph bars represent mean with standard error of the mean of three 
independent experiments with the standard error of the mean of three independent experiments. (C) Graph bars with means represent cell 
status 96 h after treatment with examples pictures of each cell status on the right. Each condition has been performed in triplicate.
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treatments options for women with recurrent cervical 
cancer after previous radiotherapy [14]. Previously 
irradiated tumors may have a lower perfusion caused by 
the irradiation inducing hypoxia, and hypoxic tumors 
are less sensitive to ionizing radiation [28–30]. Clinical 
trials have shown that HT is an effective chemosensitizer 
for cDDP [31, 32] that increases cDDP uptake in tumor 
cells and thus enhances the induction of DNA damage 
[33]. Additionally, as described earlier, hyperthermia 
also temporality inhibits one of the major DNA repair 
pathways, HR, by downregulation of BRCA2 [34, 35], 
explaining the rational for thermochemotherapy. 
However, one of the limiting effects of cDDP is 
nephrotoxicity. 
Figure 4: Addition of PARP1-i (100 μM NU1025/continuously) to the commonly used dose of cDDP (5 µM/1 h; 
cDDP/C) and HT (42°C/1 h) permits lowering of cDDP concentration (0.5 µM/1 h; cDDP/L). (A) To study apoptosis levels, 
the Nicoletti assay was performed 48 h after different treatments. No significant differences were observed between cDDP/L+HT+PARP1-i 
and cDDP/C+HT (R1: p = 0.10, SiHa: p = 0.86, HeLa: p = 0.22). (B) Time-lapse microscopy was performed 0–96 h after treatments. 
Pictures represent cells directly after treatment (0 h) and at the end of the analysis (96 h). (C) Clonogenic assays were conducted to study 
the effect 10-12 days after treatments. No significant differences were observed between cDDP/L+HT+PARP1-i and cDDP/C+HT (R1: 
p = 0.10, SiHa: p = 0.70, HeLa: p = 0.20). Graph bars show mean of at least three independent experiments with the standard error of the 
mean. Asterisks indicate the significant differences compared to the untreated sample (ctrl), tested using the non-parametric Mann-Whitney 
test. *p < 0.05, **p < 0.01, ***p < 0.001.
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Our results may have important clinical implications, 
as they suggest the possibility to diminish cDDP related 
toxicity, without reducing the desired cytotoxic effect. 
Therefore, combining a low dose of cDDP with HT and 
a PARP1-i may be a promising approach to increase 
tumor control whilst reducing systematic cDDP-toxicity, 
particularly in women with (recurrent) cervical cancer. The 
triple combination might be interesting for the treatment of 
other tumor types as well, because the treatment will also 
target tumors with wild-type BRCA status [36, 37] and it 
may also be an option for patients in whom radiotherapy 
is contra-indicated. 
To assess if not only chemotherapy, but also 
hyperthermia dose can be reduced, it is also relevant to 
further elaborate whether reduction in time at 42°C or the 
use of a lower temperature combined with chemotherapy 
and a PARP1-i can cause comparable outcome. This is of 
clinical interest, since it is not always possible to achieve 
42°C for 1 h at the tumor site. If the addition of a PARP1-i 
can be used to compensate for hyperthermia treatment at 
a shorter time or at a lower temperature, this may improve 
treatment outcome.
In several clinical trials the effect of high- and low-
dose cDDP has been compared for squamous head and 
neck carcinoma [38-40] and cervical carcinoma [41], in 
which these studies report acceptable toxicity of low-dose 
cDDP in radiochemotherapy without significant differences 
in response rate between high- and low-dose cDDP. 
Another way to decrease the severe nephrotoxicity 
caused by cDDP is to administer high-volume hydration 
in cDDP-based chemotherapy. This has been tested in 
clinical trials in patients with lung cancer [42, 43] and 
resulted in reduction of renal toxicity after high-volume 
hydration, while renal function was significantly worse 
after low-volume hydration. These effects might be related 
to osmolality, and both serum and urinary concentrations 
of cDDP [43, 44]. Likewise, as applying low-cDDP dose, a 
decrease in nephrotoxicity is achieved when administering 
high-volume hydration in patients.
Our results provide rational for adding PARP1-i 
to the standard cDDP+HT therapy, because this could 
slightly increase overall treatment efficacy, potentially 
allow reducing of cDDP concentration. It could also 
increase efficacy in tumor area that are poorly accessible 
for cDDP and it could increase efficacy in patient that are 
subjected to high-volume hydration. In vivo experiments 
need to be performed to confirm these findings. 
MATERIALS AND METHODS
Cell lines
The rat rhabdomyosarcoma cells (R1) were grown 
in MEM and the cervical carcinoma cells (SiHa and HeLa) 
were grown in EMEM. The R1 cell line was created in 
our own laboratory [44]. SiHa and HeLa cell lines were 
obtained from the American Type Culture Collection 
(ATCC). All media contain 25 mM Hepes (Gibco-BRL life 
technologies, Breda, The Netherlands) supplemented with 
10% heat-inactivated fetal bovine serum (FBS) and 2 mM 
glutamine. Cells were maintained at 37°C in an incubator 
with humidified air supplemented with respectively 2% 
and 5% CO2. The cell division time during exponential 
growth of R1 cells is approximately 16 h and of the 
cervical cancer cells 24 h.
Chemical agents
Cells were treated with an optimized concentration 
[33, 45, 46] of 5 µM for 1 h cisplatin (cDDP; Platosin®, 
Pharmachemie B.V., Haarlem, The Netherlands). For 
experiments in which low and commonly used cisplatin 
concentrations were compared, cells were treated with 
either 0.5 µM (cDDP/L) or the standard dose of 5 µM 
(cDDP/C) for 1 h, respectively. The 0.5 µM dose was 
determined by performing a titration curve on clonogenic 
assays with concentrations between 0 and 5.0 µM cDDP 
dose combined with PARP1-i – and found that a 0.5 µM 
dose was the lowest dose of cDDP where the combination 
had an effect comparable to the effect of the standard 
concentration cDDP alone. The medium was refreshed 
directly after. To inhibit the b-NHEJ and SSB repair, 
100 µM of PARP1-i (NU1025, Tocris Bioscience, Bristol, 
UK) was added 30 min prior to hyperthermia. After 
refreshing the medium, PARP1-i was re-added till the end 
of the experiment in the appropriate concentration. 
Hyperthermia
Incubation of the cells was performed by partially 
submerging the culture dishes in a thermostatically 
controlled water bath (Lauda aqualine AL12, Beun 
de Ronde, Abcoude, The Netherlands) for 1 h at 42°C. 
Temperature was checked in parallel dishes and the desired 
temperature (± 0.1°C) was reached in approximately 
5 min. The atmosphere of the water bath was adjustable. 
R1 cells were heated in a 2% CO2/98% air atmosphere and 
SiHa and HeLa cells were heated in a 5% CO2/95% air 
atmosphere with an air inflow of 2 L/min. 
Immunohistochemistry
Cells were plated 24 h prior to treatment on sterile 
coverslips or 1.8 µm mylar membrane dishes. Cells on 
coverslips were treated with cDDP, PARP1-i and/or HT, 
while cells on mylar were treated with only hyperthermia 
and directly followed by irradiation with α-particles for 
1 min. Next, cells were fixed with 2% paraformaldehyde 
after 15 min, 30 min (α-particles) or 24 h. After washing 
with PBS and incubated for 30 min with TNBS (PBS 
containing 0.1% Triton X-100 and 1% FCS), cells were 
stained with γ-H2AX (Millipore, dilution 1:100 in TNBS) 
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and RAD51 antibody (dilution 1:25 in TNBS) as described 
by Aten et al. [47]. Finally, vectashield with DAPI (Life 
technologies, USA) was dropped at the slide and the 
coverslip is turned upside down on the slide, for scoring 
under the fluorescence microscope.
Clonogenic assays 
Cell survival was studied on R1, SiHa and HeLa 
cells using different treatment combinations; hyperthermia 
(1 h at 42°C), cDDP (cDDP/C: 5 µM for approximately 
1 h, cDDP/L: 0.5 µM for approximately 1 h), PARP1-i 
(100 µM, continuously). Clonogenic assays were 
conducted as described by Franken et al. [48]. Cells were 
plated before treatment into 6-well culture plates (Costar, 
USA). Dishes were placed in an incubator with 5% CO2 
at 37°C until sufficiently large clones were formed. 
Afterwards the medium is removed and cells were washed 
with PBS. A mixture of 6.0% glutaraldehyde (2–3 ml) and 
0.5% crystal violet was added for at least 30 min at room 
temperature. Next, plates were washed with water and 
dried in normal air at room temperature. Colonies were 
counted under a light microscope [49]. Surviving fractions 
were calculated by dividing the plating efficiency of 
treated cells by that of control cells [50].
Apoptosis assay
The Nicoletti assay [51] was used to study apoptosis 
in all cell lines. At 48 h after treatment cells were collected 
and pellets were resuspended in Nicoletti buffer (0.1% 
w/v Sodium citrate, 0.1% v/v Triton X-100 in demi water, 
pH 7.4). Analyses were made using flow cytometry (FACS 
Canto, BD Biosciences, USA).
Cell cycle analysis
Cell cycle distribution was analyzed using the 
thymidine analogue 5-Bromo-2ʹ-deoxy-uridine (BrdU, 
Sigma Aldrich, USA) that can incorporate into S-phase 
cells (60 min at 37°C). BrdU was added 16 h after 
treatment and 1 h prior to fixation in 2 ml PBS and 6 ml 
of 100% ethanol. The pellet was resuspended in pepsin-
HCl (0.4 mg/ml, 0.1 N HCl) and cells were stored 30 min 
at room temperature. Cells were washed with PBT (0.5% 
Tween-20, Sigma Aldrich USA in 0.5 l PBS). The pellet 
was resuspended in HCl (2 N, Merck) and cells were 
incubated 30 min at 37°C. 100 µl primary antibody rat-anti-
BrdU (Abcam, UK) in PBTb (1% bovine serum albumin, 
Sigma, in PBT) was added 1 h at 37ºC. After washing, 
100 μl IgG goat-anti-rat FITC (Abcam, UK) in PBTg (1% 
normal goat serum, Dako, USA, in PBT) was added and left 
for 1 h at 37ºC. Final, PI (Sigma-Aldrich, USA) was added, 
cell suspensions were vortexed and directly measured using 
flow cytometry (FACS Canto, BD Biosciences, USA). 
Time-lapse microscopy
Cells were grown in 6-wells plates for 24 h, 
before treatments. Dishes were placed under a confocal 
microscope (Leica PS2, The Netherlands) with a 
temperature and CO2/air controlled chamber and cells 
were imaged for 96 h. A minimum of fifty cells were 
analyzed per condition. 
Statistics
All represented in vitro data are means ± 
standard error of the mean of at least three independent 
experiments. Cell survival and apoptosis were analyzed 
using SPSS (Chicago, IL, USA) statistical software using 
a non-parametric Mann-Whitney test. 
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